Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Alveolar soft part sarcoma (ASPS)

Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Alveolar soft part sarcoma (ASPS) is a malignant soft tissue tumor, which is a tumor that starts in the soft connective tissues of the body such as fat, muscles, or nerves. The two genes involved in ASPS are the alveolar soft part sarcoma critical region 1 (ASPSCR1) gene on chromosome 17 and TFE3 gene on chromosome X. In ASPS, the TFE3 gene breaks off from the X chromosome and attaches onto the ASPSCR1 gene on chromosome 17. This unbalanced translocation creates a new so-called “fusion” gene known as ASPSCR1-TFE3.

Epidemiology-

ASPS is one of the rarest sarcomas. Soft tissue sarcomas make up 1% of all cancers and ASPS makes up only 0.2% to 1% of all soft tissue sarcomas. There are about 80 cases diagnosed per year in the United States.

Competitive landscape of Alveolar soft part sarcoma (ASPS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Alveolar soft part sarcoma (ASPS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Alveolar soft part sarcoma (ASPS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company         Stage
1          GB226 Genor    Biopharma Co., Ltd. Phase 2
2.         AL3818 Advenchen Laboratories, LLC Phase 3
3          Axitinib and Pembrolizumab       Merck Sharp & Dohme Corp. Phase 2
4          Perifosine         AEterna Zentaris Phase 2
5          FAZ053            Novartis Pharmaceuticals Phase 1